Title:
ALBUMIN FUSION PROTEINS
Document Type and Number:
WIPO Patent Application WO2001079271
Kind Code:
A9
Abstract:
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Inventors:
BALLANCE DAVID JAMES (US)
SLEEP DARRELL (US)
TURNER ANDREW JOHN (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
SLEEP DARRELL (US)
TURNER ANDREW JOHN (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
Application Number:
PCT/US2001/012009
Publication Date:
February 28, 2002
Filing Date:
April 12, 2001
Export Citation:
Assignee:
PRINCIPIA PHARMACEUTICAL CORP (US)
DELTA BIOTECHNOLOGY LTD (GB)
BALLANCE DAVID JAMES (US)
SLEEP DARRELL (US)
TURNER ANDREW JOHN (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
DELTA BIOTECHNOLOGY LTD (GB)
BALLANCE DAVID JAMES (US)
SLEEP DARRELL (US)
TURNER ANDREW JOHN (US)
SADEGHI HOMAYOUN (US)
PRIOR CHRISTOPHER P (US)
International Classes:
C12N15/09; A61K35/12; A61K35/76; A61K38/00; A61K38/21; A61K38/22; A61K38/23; A61K38/27; A61K38/28; A61K38/43; A61K38/46; A61K38/48; A61K38/55; A61K39/395; A61K47/48; A61K48/00; A61P1/00; A61P1/04; A61P1/16; A61P1/18; A61P3/10; A61P3/14; A61P5/00; A61P5/10; A61P5/14; A61P5/40; A61P7/00; A61P7/04; A61P7/06; A61P9/00; A61P9/06; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/00; A61P13/02; A61P13/08; A61P13/12; A61P15/00; A61P15/08; A61P15/10; A61P15/18; A61P17/00; A61P17/02; A61P17/06; A61P17/12; A61P17/14; A61P19/00; A61P19/02; A61P19/08; A61P19/10; A61P21/00; A61P21/04; A61P25/00; A61P25/02; A61P25/08; A61P25/16; A61P25/28; A61P27/02; A61P29/00; A61P31/00; A61P31/12; A61P31/14; A61P31/16; A61P31/18; A61P31/20; A61P31/22; A61P33/02; A61P33/06; A61P33/12; A61P35/00; A61P35/02; A61P35/04; A61P37/00; A61P37/02; A61P37/04; A61P37/06; A61P37/08; A61P39/02; A61P41/00; A61P43/00; C07K14/47; C07K14/55; C07K14/56; C07K14/565; C07K14/585; C07K14/60; C07K14/61; C07K14/62; C07K14/635; C07K14/65; C07K14/705; C07K14/715; C07K14/745; C07K14/75; C07K14/76; C07K14/765; C07K14/81; C07K16/00; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/02; C12N5/10; C12N9/14; C12N9/74; C12N9/99; C12N15/62; A61K39/00; (IPC1-7): C07K14/00; C07H21/04; C12N15/00; A61K38/16
Download PDF:
Previous Patent: MIGRAINE AND VASODILATION TREATMENT
Next Patent: SITOSTEROLEMIA SUSCEPTIBILITY GENE (SSG): COMPOSITIONS AND METHODS OF USE
Next Patent: SITOSTEROLEMIA SUSCEPTIBILITY GENE (SSG): COMPOSITIONS AND METHODS OF USE